David Beier, J.D.

Mr. Beier has served as a member of our board since December 2017. Mr. Beier brings extensive experience in the biopharmaceutical industry, particularly in areas such as healthcare policy, government affairs, regulatory affairs, pricing, healthcare economics and product commercialization. He is currently a Managing Director at Bay City Capital, where he has been since 2013. He also serves as an appointee of Governor Brown on the California State Government Organization and the Economy Commission. In addition, Mr. Beier is an advisor to the Parker Institute for Cancer Immunotherapy. Previously, Mr. Beier served in the White House as Chief Domestic Policy Advisor to Vice President Gore during the Clinton Administration. He served as an appointee of President Clinton on his Advisory Committee for Trade Policy and Negotiations, on the Institute of Medicine panel on the Future of Health and Human Services, and as an advisor to the President’s Council of Advisors on Science and Technology. Mr. Beier was formerly a partner at Hogan and Hartson and Counsel to the U.S. House of Representatives Committee on the Judiciary. Mr. Beier’s industry experience includes 9 years at Genentech as Vice President, Government Affairs and Policy as well as over 10 years at Amgen as Senior Vice President, Global Government Affairs and Corporate Affairs, where he had responsibility for public policy, coverage and reimbursement, payor planning, healthcare economics, communications and philanthropy. He received his J.D. from Albany Law School at Union University and his undergraduate degree and Colgate University. He is admitted to practice law in New York and the District of Columbia.

Kathryn Falberg

Ms. Falberg has served as a member of the board since September 2017. Previously, she served as Executive Vice President and Chief Financial Officer of Jazz Pharmaceuticals plc, a multinational specialty biopharmaceutical company, from March 2012 to March 2014 after serving as Senior Vice President and Chief Financial Officer since December 2009. Her responsibilities at Jazz Pharmaceuticals included strategy, corporate development, corporate communications, and information technology. From 1995 to 2001, Ms. Falberg was with Amgen Inc., a biotechnology company, where she served as Senior Vice President, Finance and Strategy, and Chief Financial Officer; and prior to that she was Vice President, Chief Accounting Officer, and Vice President, Treasurer. Ms. Falberg currently serves as a member of the Board of Directors for the public biopharmaceutical companies Aimmune Therapeutics, Inc., aTyr Pharma, Inc., Axovant Sciences and The Trade Desk, Inc., and recently served on the Board of Directors of Medivation until its acquisition by Pfizer.  Ms. Falberg received an M.B.A. in finance and a B.A. in economics from the University of California, Los Angeles. She is a certified public accountant (inactive).

Kristen Hege, M.D.

Kristen Hege has served as a member of our board of directors since October 2018. Dr. Hege is currently a Clinical Professor of Medicine, Hematology and Oncology and an attending physician at the University of California, San Francisco (UCSF). She has held a clinical faculty appointment at UCSF since 1997 in the adult hematology and bone marrow transplant program. Dr. Hege has been board-certified in internal medicine, medical oncology and hematology. Dr. Hege received her B.A. summa cum laude from Dartmouth, M.D. from UCSF and completed a medical residency at Brigham & Women’s Hospital, Harvard Medical School and a fellowship in hematology and oncology at UCSF. She serves on the Board of Directors of the Society for Immunotherapy of Cancer, and Mersana Therapeutics and the Strategic Advisory Group for the Parker Institute for Cancer Immunotherapy. In 2015, FierceBiotech recognized her as one of the top 12 women in Biopharma.

Dr. Hege currently serves as Corporate Vice President, Translational Development, Hematology and Oncology and San Francisco site head at Celgene where she is responsible for translational and early clinical development for all hematology and oncology products including small molecules, biologics and cell therapies. Prior to joining Celgene, she served as acting Chief Medical Officer at Aragon Pharmaceuticals, Theraclone Sciences and Cellerant Therapeutics. Dr. Hege began her career at Cell Genesys Inc. where she spent 14 years in various roles of increasing responsibility, ultimately leading the Clinical Research and Development organization.

Juan Jaen, Ph.D. (President)

Dr. Jaen has been engaged in all aspects of drug discovery and development for more than 30 years. In 2015, he co-founded Arcus Biosciences together with Terry Rosen. Prior to that, he was co-founder and President/Head of R&D at Flexus Biosciences, until its acquisition by Bristol-Myers Squibb for $1.25 billion. Previously, he was Chief Scientific Officer and Senior Vice President of Drug Discovery at ChemoCentryx. During his tenure there of just under 7 years, Juan led the discovery and progression into the clinic of 8 novel drug candidates in the immunology space. At ChemoCentryx, Juan led the discovery efforts for the multi-year collaboration with GSK, which generated over $100M in non-dilutive milestones and fees. From 1996 to 2006, Juan held various scientific management positions at Tularik (responsible for about 100 scientists in Medicinal and Computational Chemistry, as well as Structural Biology) and then Amgen Inc. (after its acquisition of Tularik in 2004), most recently as Vice President of Chemistry.

From 1983 to 1996, Dr. Jaen held various scientific leadership positions at Parke-Davis/Warner-Lambert. Dr. Jaen holds a Visiting Scholar appointment (ChEM-H) at Stanford University and is a member of the Scientific Advisory Board at Cleave Biosciences. Juan obtained a B.S. degree in Chemistry from Universidad Complutense in Madrid (Spain) and a Ph.D. degree in Organic Chemistry from the University of Michigan. He has co-authored over 100 scientific papers and is an inventor on 50 issued U.S. patents. Dr. Jaen has been responsible for the advancement of over 20 novel molecules into clinical development for diseases including cancer, Alzheimer’s, Crohn’s, RA, diabetes and diabetic nephropathy, psoriasis, asthma, and vasculitis, among others.

Jennifer Jarrett, M.B.A.

Ms. Jarrett has served as a member of our board since January 2019. Ms. Jarrett currently serves as Vice President, Corporate Development and Capital Markets at Uber and is responsible for all of their M&A and capital markets activities. Most recently, she served as Chief Financial Officer and Chief Operating Officer at Arcus Biosciences, where she was responsible for finance, accounting, investor relations, strategy, human resources and business development. Ms. Jarrett played an important role in leading Arcus’s initial public offering. Prior to joining Arcus, she served as Chief Financial Officer at Medivation until its acquisition by Pfizer in 2016.

Prior to Medivation, Ms. Jarrett spent 20 years in investment banking, most of that time covering biotechnology companies. Ms. Jarrett served as a Managing Director at Citigroup where she headed up their west coast life sciences investment banking group. Ms. Jarrett also worked in the investment banking divisions of Credit Suisse, Donaldson, Lufkin & Jenrette, Merrill Lynch and Kidder Peabody. Ms. Jarrett currently serves on the Board of Directors of Arena Pharmaceuticals, Audentes Therapeutics and Syndax Pharmaceuticals. Ms. Jarrett received her M.B.A from the Stanford Graduate School of Business and her undergraduate degree in Economics from Dartmouth College.

Yasunori Kaneko, M.D.

Yasunori Kaneko, M.D. has served as a member of our board of directors since May 2015. Dr. Kaneko has been a managing director at Skyline Venture Partners, L.P., a venture capital firm, since 1999. Previously, Dr. Kaneko served on the board of LeukoSite Inc., a biopharmaceutical company, until its merger with Millennium Pharmaceuticals, Inc. in 1999. Dr. Kaneko also served as Chief Financial Officer and Vice President, Business Development at Tularik, Inc., a biopharmaceutical company, from 1992 until 1998. Dr. Kaneko served as a Senior Vice President and Chief Financial Officer of Ionis Pharmaceuticals, Inc., a biopharmaceutical company, which went public in May 1991 during his tenure. Dr. Kaneko began his career at Genentech, where he served in a business development role, a biotechnology company, and as head of corporate finance in the investment banking division of Paribas Capital Markets LTD in Tokyo. Dr. Kaneko received an undergraduate degree and a M.D. degree from Keio University in Tokyo, and an M.B.A. from Stanford Business School. He currently serves as a member of the Dean of Research Advisory Council at Stanford University.

Antoni (Toni) Ribas, M.D., Ph.D.

Dr. Ribas is an internationally recognized physician-scientist who conducts translational and clinical research aimed at understanding how the immune system can be used to treat cancer.  He has been a leader in the research and clinical development of multiple types of therapeutic agents, including immune checkpoint inhibitors, gene-engineered T cells, and BRAF-targeted therapies. His efforts have been instrumental in transforming the treatment paradigm for oncology patients, particularly those with malignant melanoma, having served as principal investigator for multiple trials, including those involving the breakthrough cancer therapy, Keytruda®.

Dr. Ribas is Professor of Medicine, Surgery, and Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA), Director of the Tumor Immunology Program at the UCLA Jonsson Comprehensive Cancer Center, and Director of the Parker Institute for Cancer Immunotherapy Center at UCLA. He is currently the President-Elect for the American Association for Cancer Research (AACR). Dr. Ribas has founded or advised several successful biopharma companies in addition to Arcus, such as Kite Pharma and Flexus Biosciences. Most recently, he co-founded PACT Pharma, a company developing personalized cancer neoantigen-targeted T cell therapies, together with Professors David Baltimore and Jim Heath and Arcus co-founders, Terry Rosen and Juan Jaen. Dr. Ribas has been a member of the Arcus Scientific Advisory Board since its creation in 2015.

Dr. Ribas received MD and PhD degrees from the Universidad de Barcelona (Spain). He completed his internship and residency in medical oncology at the University Hospital Vall d’Hebron (Barcelona, Spain) and conducted postdoctoral research at UCLA. Following a fellowship in hematology/oncology in the Department of Medicine at UCLA, he has held numerous faculty and administrative positions at UCLA since 2001. Dr. Ribas has received a myriad of awards and honors, including the AACR-CRI Lloyd J. Old Award in Cancer Immunology, the AACR Richard and Hinda Rosenthal Award and the National Cancer Institute (NCI) Outstanding Investigator Award. Dr. Ribas has also served on the Board of Directors of leading scientific organizations such as the AACR and the Society for Immunotherapy for Cancer (SITC).

Terry Rosen, Ph.D. (CEO)

Terry has been leading successful drug discovery and development organizations in the biotechnology and pharmaceutical industries for over 30 years. In 2015, he co-founded Arcus Biosciences, a drug discovery company focused on the treatment of cancer by blocking tumor-induced immunosuppression. Previously, he was co-founder and CEO of Flexus Biosciences, a company created to develop small-molecule drugs to reverse tumor immunosuppression, which was acquired by Bristol-Myers Squibb early in 2015 for $1.25 billion. Prior to Flexus, Terry served as Vice President, Therapeutic Discovery (TD) at Amgen and as the site head for Amgen South San Francisco, having joined Amgen with the acquisition of Tularik in 2004. He was named Amgen Washington site head in 2006, transitioned to a leadership role heading Chemistry Research and Discovery in 2007 and became the head of Protein Sciences in 2011. He and his leadership team were responsible for the creation of the TD organization, a group of 550+ staff responsible for all of Amgen’s large and small molecule drug discovery efforts.

Prior to joining Amgen, Terry held several executive positions at Tularik, including Executive Vice President, Operations, Vice President, Research Operations, and Vice President, Medicinal Chemistry. He has also held scientific and management positions at Pfizer and Abbott Laboratories. Terry serves on the Salk Institute Board of Trustees, the SAB and leadership committees of the University of Michigan Life Sciences Institute, the Board of Trustees of the UC Berkeley Foundation, the Caltech Biology & Bioengineering Chair’s Council and the Board of the California Life Sciences Association.​